Catalent (NYSE:CTLT) said today that its subsidiary, Catalent Pharma Solutions, plans to offer $450 million in senior unsecured notes due 2026.
The private offering will be used to fund, in part, the drug-delivery company’s $950 million purchase of biologics manufacturer, Cook Pharmica.
Get the full story at our sister site, Drug Delivery Business News.
The post Catalent launches $450m private offering appeared first on MassDevice.